Jupiter Bioscience- Rs.143.00

Established in 1985, Jupiter Bioscience Limited (JBL) is among the few pharma companies in the world with core competence in peptide chemistry, organic chemistry, chiral chemistry and biotechnology. In fact, JBL was the first company in Asia to introduce and commercialise molecules based on peptide chemistry. It has three specialised product lines viz. Peptide reagents and protected amino acids, Drug intermediates & Speciality Chemicals as well as fine chemicals. JBL has two manufacturing facilities - one at Bidar in Karnataka and the other at Cheriyal in Medak District in Andhra Pradesh, which is a 100% EOU. JBL is very strong not only in research & development but also in process development with its focus on advanced organic and peptide chemistries. It has constantly introduced new peptide reagents, coupling reagents and protected amino acids in the market.

With the successful launch of peptide precursors, the main raw materials for generic peptide drugs, JBL is now globally positioned to manufacture key raw materials for peptide pharmaceuticals in lab scale quantities, pilot scale quantities and commercial quantities. It has developed expertise in peptide precursors in Diagnostics, Vaccines and Peptide Antibiotics apart from concentrating on research of new peptide molecules. JBL is also moving up the value chain to commercialise and introduce generic peptide drugs such as Oxytocin, Vasopressin, Desmopressin, Leuprolide, Lisinopril and Calcitonin in the domestic and international markets. Its thrust has been on Multi-process capabilities of Pharmaceutical intermediates and API's. Lately, it renewed its interest in Speciality Drug Intermediates for treatment of cardiovascular diseases, AIDS and Cancer. To increase it global presence, JBL is aggressively participating in exhibitions, fairs and trade shows all over the world. Moreover, it is presently working on suitable entry strategies into the US and European markets through appropriate alliances. Notably, JBL has following 3 subsidiaries:

Jupiter Bioscience – India which specializes in Manufacturing Drug Intermediates, Specialty Chemicals, Peptide Reagents and Protected Amino Acids.

Sven Genetech – India which specializes in small volume side chain Protected Amino Acids, Peptides, Beta Amino Acids and Unusual Amino Acids. It has established in-house facilities for microbiology and biochemistry to carry out development and scaling up of enzymes and protein purification.

Jupiter Bioscience – USA which offers Custom Peptides from USA and is in process of establishing a facility in USA for offering Clinical and Generic Peptide Bulk Actives.

The year 2005 is a major eventful year wherein patents for a majority of the drugs in the world will expire and open up a huge market for pharmaceutical companies worldwide. JBL is growing steadily year after year with FY05 Sales increasing 7% to Rs.70.50 cr. and the NP growth of 21% to 18.50 cr. For future growth plans, JBL is planning to raise capital through ADR/GDR/FCCB and is also making preferential allotment of 27.50 lakh shares to promoters. Considering these factors, JBL is expected to report Sales of Rs.80 cr. and NP Rs.21 cr. which can lead to on an EPS of Rs.18 on its expanded equity of Rs.11.60 cr. Only aggressive investors are recommended to buy this scrip with a price target of Rs.220 in 6~9 months.